3.237.27.159
dgid:
enl:
npi:0
Conference Roundup
Neurology

New Data Continues to Demonstrate Efficacy of Ofatumumab for Relapsing Forms of Multiple Sclerosis

Posted on

Within the first year of treatment, approximately 47% of patients with relapsing forms of multiple sclerosis (RMS) taking ofatumumab showed no evidence of disease compared to approximately 24% of those treated with teriflunomide, according to data from the Phase III ASCLEPIOS trials and the Phase II APLIOS trial presented virtually at the 6th Congress of the European Academy of Neurology (EAN). During the second year of treatment, 87.8% of patients treated with ofatumumab had no evidence of disease compared with 48% of patients taking teriflunomide.

“Achieving no evidence of disease activity is widely recognized as an important treatment goal for multiple sclerosis therapies,” said Professor Ludwig Kappos, University Hospital Basel in a press release. “These data suggest that halting new disease activity is possible by targeted B-cell therapy in RMS.”

The U.S. Food and Drug Administration is expected to make a regulatory decision regarding ofatumumab in June 2020.

Read the full press release here.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-